Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome.

Somaye Barashki, Ghasemali Divband, Emran Askari, Hamidreza Amini, Kamran Aryana

Clinical nuclear medicine 2022 Mar 01

filter terms:

A patient with multiple endocrine neoplasia type 2A syndrome who had exhausted several surgeries and radiotherapy was referred to nuclear medicine department for theranostic approaches. [68Ga]-DOTATATE PET/CT and [131I]I-mIBG SPECT/CT were performed, but the degree of uptake was insufficient for using the treatment companion of these tracers. Finally, 1 year later, [68Ga]-FAPI-46 PET/CT showed progressive disease with metastases to the lung, liver, bone, and lymph nodes with intense [68Ga]-FAPI-46 uptake. Treatment with [177Lu]Lu-FAPI-46 was done, and the patient tolerated treatment and showed evidence of clinical improvement following therapy. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Somaye Barashki, Ghasemali Divband, Emran Askari, Hamidreza Amini, Kamran Aryana. Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome. Clinical nuclear medicine. 2022 Mar 01;47(3):e284-e286